The positive effects of exercise in chemotherapy-related cardiomyopathy

Cavarretta Elena, Mastroiacovo Giorgio, Lupieri Annik, Frati Giacomo, Peruzzi Mariangela

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin, are powerful chemotherapeutic drugs used both in children and adult populations. Their properties made them particularly suitable for a large variety of neoplasms including breast adenocarcinoma, small cell lung cancer and acute leukemia. Early and late anthracycline-induced cardiotoxicity is a well-known phenomenon, and the incidence of heart failure in patients receiving doxorubicin is 2.2%, with a mortality rate over 60% at 2 years. Prognosis can be improved by prevention, early detection and treatment. A specific treatment for anthracycline-induced cardiotoxicity is not yet available, but non-pharmacological measures such as exercise, lifestyle changes and control of risk factors have shown a cardioprotective effect. Exercise training represents a viable non-pharmacological treatment as it increases cardiovascular reserve and endothelial function, regulates proapoptotic signaling, protects against reactive oxygen species (ROS), and decreases autophagy/lysosomal signaling. However, no current guidelines are available for prevention management in cancer patients. Pharmacological measures both for prevention and treatment are those used for heart failure (β-blockers, angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, statins, dexrazoxane and aldosteron antagonists). In this chapter, we will discuss how the evaluation, monitoring and prevention of chemotherapy-related cardiomyopathy is correlated with physical exercise.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages103-129
Number of pages27
Volume1000
DOIs
Publication statusPublished - Jan 1 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1000
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Chemotherapy
Anthracyclines
Cardiomyopathies
Exercise
Drug Therapy
Doxorubicin
Dexrazoxane
Idarubicin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mitoxantrone
Epirubicin
Daunorubicin
Heart Failure
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Reactive Oxygen Species
Small Cell Lung Carcinoma
Autophagy
Therapeutics
Cells

Keywords

  • Anthracycline
  • Cardiotoxicity
  • Chemotherapy-related cardiomyopathy
  • Exercise
  • Prevention

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Elena, C., Giorgio, M., Annik, L., Giacomo, F., & Mariangela, P. (2017). The positive effects of exercise in chemotherapy-related cardiomyopathy. In Advances in Experimental Medicine and Biology (Vol. 1000, pp. 103-129). (Advances in Experimental Medicine and Biology; Vol. 1000). Springer New York LLC. https://doi.org/10.1007/978-981-10-4304-8_8

The positive effects of exercise in chemotherapy-related cardiomyopathy. / Elena, Cavarretta; Giorgio, Mastroiacovo; Annik, Lupieri; Giacomo, Frati; Mariangela, Peruzzi.

Advances in Experimental Medicine and Biology. Vol. 1000 Springer New York LLC, 2017. p. 103-129 (Advances in Experimental Medicine and Biology; Vol. 1000).

Research output: Chapter in Book/Report/Conference proceedingChapter

Elena, C, Giorgio, M, Annik, L, Giacomo, F & Mariangela, P 2017, The positive effects of exercise in chemotherapy-related cardiomyopathy. in Advances in Experimental Medicine and Biology. vol. 1000, Advances in Experimental Medicine and Biology, vol. 1000, Springer New York LLC, pp. 103-129. https://doi.org/10.1007/978-981-10-4304-8_8
Elena C, Giorgio M, Annik L, Giacomo F, Mariangela P. The positive effects of exercise in chemotherapy-related cardiomyopathy. In Advances in Experimental Medicine and Biology. Vol. 1000. Springer New York LLC. 2017. p. 103-129. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-981-10-4304-8_8
Elena, Cavarretta ; Giorgio, Mastroiacovo ; Annik, Lupieri ; Giacomo, Frati ; Mariangela, Peruzzi. / The positive effects of exercise in chemotherapy-related cardiomyopathy. Advances in Experimental Medicine and Biology. Vol. 1000 Springer New York LLC, 2017. pp. 103-129 (Advances in Experimental Medicine and Biology).
@inbook{381bfec4967d4fb9b302c6d024b8859e,
title = "The positive effects of exercise in chemotherapy-related cardiomyopathy",
abstract = "Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin, are powerful chemotherapeutic drugs used both in children and adult populations. Their properties made them particularly suitable for a large variety of neoplasms including breast adenocarcinoma, small cell lung cancer and acute leukemia. Early and late anthracycline-induced cardiotoxicity is a well-known phenomenon, and the incidence of heart failure in patients receiving doxorubicin is 2.2{\%}, with a mortality rate over 60{\%} at 2 years. Prognosis can be improved by prevention, early detection and treatment. A specific treatment for anthracycline-induced cardiotoxicity is not yet available, but non-pharmacological measures such as exercise, lifestyle changes and control of risk factors have shown a cardioprotective effect. Exercise training represents a viable non-pharmacological treatment as it increases cardiovascular reserve and endothelial function, regulates proapoptotic signaling, protects against reactive oxygen species (ROS), and decreases autophagy/lysosomal signaling. However, no current guidelines are available for prevention management in cancer patients. Pharmacological measures both for prevention and treatment are those used for heart failure (β-blockers, angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, statins, dexrazoxane and aldosteron antagonists). In this chapter, we will discuss how the evaluation, monitoring and prevention of chemotherapy-related cardiomyopathy is correlated with physical exercise.",
keywords = "Anthracycline, Cardiotoxicity, Chemotherapy-related cardiomyopathy, Exercise, Prevention",
author = "Cavarretta Elena and Mastroiacovo Giorgio and Lupieri Annik and Frati Giacomo and Peruzzi Mariangela",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-981-10-4304-8_8",
language = "English",
volume = "1000",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "103--129",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - The positive effects of exercise in chemotherapy-related cardiomyopathy

AU - Elena, Cavarretta

AU - Giorgio, Mastroiacovo

AU - Annik, Lupieri

AU - Giacomo, Frati

AU - Mariangela, Peruzzi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin, are powerful chemotherapeutic drugs used both in children and adult populations. Their properties made them particularly suitable for a large variety of neoplasms including breast adenocarcinoma, small cell lung cancer and acute leukemia. Early and late anthracycline-induced cardiotoxicity is a well-known phenomenon, and the incidence of heart failure in patients receiving doxorubicin is 2.2%, with a mortality rate over 60% at 2 years. Prognosis can be improved by prevention, early detection and treatment. A specific treatment for anthracycline-induced cardiotoxicity is not yet available, but non-pharmacological measures such as exercise, lifestyle changes and control of risk factors have shown a cardioprotective effect. Exercise training represents a viable non-pharmacological treatment as it increases cardiovascular reserve and endothelial function, regulates proapoptotic signaling, protects against reactive oxygen species (ROS), and decreases autophagy/lysosomal signaling. However, no current guidelines are available for prevention management in cancer patients. Pharmacological measures both for prevention and treatment are those used for heart failure (β-blockers, angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, statins, dexrazoxane and aldosteron antagonists). In this chapter, we will discuss how the evaluation, monitoring and prevention of chemotherapy-related cardiomyopathy is correlated with physical exercise.

AB - Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin, are powerful chemotherapeutic drugs used both in children and adult populations. Their properties made them particularly suitable for a large variety of neoplasms including breast adenocarcinoma, small cell lung cancer and acute leukemia. Early and late anthracycline-induced cardiotoxicity is a well-known phenomenon, and the incidence of heart failure in patients receiving doxorubicin is 2.2%, with a mortality rate over 60% at 2 years. Prognosis can be improved by prevention, early detection and treatment. A specific treatment for anthracycline-induced cardiotoxicity is not yet available, but non-pharmacological measures such as exercise, lifestyle changes and control of risk factors have shown a cardioprotective effect. Exercise training represents a viable non-pharmacological treatment as it increases cardiovascular reserve and endothelial function, regulates proapoptotic signaling, protects against reactive oxygen species (ROS), and decreases autophagy/lysosomal signaling. However, no current guidelines are available for prevention management in cancer patients. Pharmacological measures both for prevention and treatment are those used for heart failure (β-blockers, angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, statins, dexrazoxane and aldosteron antagonists). In this chapter, we will discuss how the evaluation, monitoring and prevention of chemotherapy-related cardiomyopathy is correlated with physical exercise.

KW - Anthracycline

KW - Cardiotoxicity

KW - Chemotherapy-related cardiomyopathy

KW - Exercise

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=85032958327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032958327&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-4304-8_8

DO - 10.1007/978-981-10-4304-8_8

M3 - Chapter

AN - SCOPUS:85032958327

VL - 1000

T3 - Advances in Experimental Medicine and Biology

SP - 103

EP - 129

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -